This week's collection of venture capital financings in the biotech arena includes rounds for Celea, Beeline, Flare, Lycia, and Telum. PureTech's Celea eyes phase 3 for IPF drug after $180m round Armed with an impressive $180 million financing, Celea Therapeutics has hatched a plan to start an ambitious phase 3 trial of its lead drug, a modified derivative of Roche's Esbriet (pirfenidone), in patients with idiopathic pulmonary fibrosis.